Company Overview and News

5
Recent Stock Purchase October 2018

2018-10-18 seekingalpha
Market volatility is back. We're up, we're down, red flags about the economy, world affairs, interest rates (add whatever concern here), and you can go mad trying to make sense of it all. That's why it's sometimes better to simply invest with blinders on. Follow your own path and rules and tune out all the financial noise. See, the headlines are always going to be negative in good economic times and, of course, bad.
VTR CAH SBRA SBRAP

 
Dividend Income Update September 2018

2018-10-09 seekingalpha
The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. No doubt, these are the best posts to write and read online as it only provides further proof that dividend investing can work over time and that anyone can create an ever growing passive income stream. Looking back at my September totals, I see that my year-over-year progress is moving at a nice clip.
VTR SBRA SBRAP

 
Sabra Health Care REIT, Inc. to Attend the NIC Fall Conference

2018-10-04 globenewswire
IRVINE, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Sabra Health Care REIT, Inc. (Nasdaq: SBRA) announced today that Rick Matros, the company’s Chairman and Chief Executive Officer, Talya Nevo-Hacohen, the company’s Chief Investment Officer, Brent Chappell, the company’s Executive Vice President of Portfolio Management, and Tri Tran, the company’s Senior Vice President of Investments, will be attending the NIC Fall Conference on October 17 - 19 at the Sheraton Grand in Chicago.
SBRA SBRAP

13
October 2018 Stock Considerations

2018-10-02 seekingalpha
Here we go again. A new month is upon us, which means one thing... time for me to outline my potential stock picks for October. I can hardly believe that we are now entering the final quarter of 2018, but here we are. Where does the time go? Whenever I reflect on how fast the days, weeks and months roll by, I am reminded of the importance to always stay "fully" invested in the stock market. By now you know that I make my purchases every single month no matter what domestic or foreign event is taking place.
D HCP KHC SBRA SBRAP

 
Sabra Health Care REIT Presents Bank of America Merrill Lynch Real Estate Conference, Sept. 25 2018

2018-09-26 seekingalpha
The following slide deck was published by Sabra Health Care REIT, Inc. in conjunction with this event.
SBRA SBRAP

 
Stepping Outside The Sabra Box

2018-09-25 seekingalpha
No need for a victory lap, the purpose for this article is to determine whether or not to continue with SBRA.
MPW OHI CCP SBRA SBRAP

10
September 2018 Stock Considerations

2018-09-14 seekingalpha - 1
A little late with this post as I like to highlight my potential stock buys in the beginning of the month but sometimes it can be tough deciding where to deploy fresh capital when many stocks are trading at premium prices. Of course, we all know that no matter how high the market rises, there will always be a gem in the rough lurking somewhere. With that being said, let's take a look at some of my September stock considerations.
D HCP PPL SBRA SBRAP

 
Sabra Health Care REIT, Inc. to Attend the Bank of America Merrill Lynch Global Real Estate Conference

2018-09-12 globenewswire
IRVINE, Calif., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Sabra Health Care REIT, Inc. (Nasdaq: SBRA) announced today that Rick Matros, the company’s Chairman and Chief Executive Officer, Harold Andrews, the company’s Chief Financial Officer, and Talya Nevo-Hacohen, the company’s Chief Investment Officer, will be attending the Bank of America Merrill Lynch Global Real Estate Conference on September 25 - 26 at The Wagner in New York, NY.
SBRA SBRAP

1
Why Not Buy This 7.7%-Yielding Healthcare REIT?

2018-08-25 seekingalpha - 1
Sabra Health Care REIT is an interesting high-yield income vehicle with a focus on the SNF-sector.
SBRA SBRAP

 
SBRAP / Sabra Healthcare REIT, Inc. / COHEN & STEERS INC - null (Passive Investment)

2018-08-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Initial Filing) Sabra Health Care REIT, Inc. ------------------------------ (Name of Issuer) Common Stock ----------------- (Title of Class of Securities) 78573L106 ---------
SBRAP

 
SBRAP / Sabra Healthcare REIT, Inc. / COHEN & STEERS INC - null (Passive Investment)

2018-08-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Initial Filing) Sabra Health Care REIT, Inc. ------------------------------ (Name of Issuer) Common Stock ----------------- (Title of Class of Securities) 78573L106 ---------
SBRAP

4
Sabra Health Care REIT, Inc. (SBRA) CEO Rick Matros on Q2 2018 Results - Earnings Call Transcript

2018-08-10 seekingalpha
Sabra Health Care REIT, Inc. (NASDAQ:SBRA) Q2 2018 Results Earnings Conference Call August 9, 2018 1:00 PM ET
WFC WFCNP SIA SIA.DB SBRA SBRAP

 
Sabra and PointRight Announce Strategic Partnership to Provide Post-Acute Analytics to Manage and Improve Outcomes

2018-07-17 globenewswire
IRVINE, Calif., July 17, 2018 (GLOBE NEWSWIRE) -- Sabra Health Care REIT, Inc. (Nasdaq:SBRA) and PointRight® announced a strategic partnership to provide post-acute analytics to Sabra’s Skilled Nursing Facility (“SNF”) portfolio. Through this partnership, Sabra’s SNF tenants and operators can participate in a collaborative program that provides PointRight’s clinical and business intelligence tools to help them manage and improve outcomes in their facilities.
SBRA SBRAP

1
Sabra Health Care Disposes Genesis & Signature Facilities

2018-07-12 zacks
Recently, Sabra Health Care REIT (SBRA - Free Report) announced the selling of nine healthcare facilities leased to Genesis Healthcare (GEN - Free Report) on Jun 29, in a bid to dispose the properties leased to the latter. These healthcare facilities have been sold for $81.4 million.
CXP PSB SBRA ADI GEN SBRAP

 
Sabra Health Care REIT, Inc. Completes the Sale of Nine Facilities Leased to Genesis; Sells a Facility Leased to Signature HealthCARE

2018-07-09 globenewswire
IRVINE, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Sabra Health Care REIT, Inc. (Nasdaq:SBRA) announced today that on June 29, 2018, it completed the previously announced sale of nine facilities (seven skilled nursing facilities, one senior housing community and one continuing care retirement community) leased to Genesis Healthcare, Inc. (“Genesis”) for $81.4 million. Under the terms of Sabra’s memoranda of understanding with Genesis, Genesis’s annual rent obligations to Sabra were reduced by $7.
GEN CCP SBRA SBRAP

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 78573L106